Aryastha Life Sciences Secures Series A Funding from Vessella Group to Accelerate Drug Discovery and Development
This funding infusion aims to speed up drug discovery and development initiatives in pharmaceuticals and biotechnology.
Aryastha Life Sciences, Hyderabad, has secured an undisclosed amount in Series A funding, driven by a significant investment from Vessella Group.
The primary objective behind this funding infusion is to expedite the progress of drug discovery and development initiatives within pharmaceuticals and biotechnology.
As a Life Science company headed by Raghava Reddy Kethiri and Dr. Pradip K. Majumder, Aryastha specialises in Contract Research and Development for Novel Drug Development.
By leveraging Artificial Intelligence (AI), sophisticated preclinical models derived from patient samples, and pluripotent stem cells, the company has carved a niche in drug screening. As a result, a more streamlined and effective service spectrum is created, addressing the pharmaceutical industry's challenges more effectively.
Established in 2023, Aryastha is an innovation-centric force in the Life Science domain. Operating from Hyderabad, India, Aryastha is known for its advanced R&D capabilities; the company has emerged in the pharmaceutical and biotechnology sectors.
Further, the company plans to accelerate by utilising technologies such as artificial intelligence, advanced preclinical models derived from patient samples, and pluripotent stem cells '“ resulting in 'Aryastha's Bio Solutions' that will enhance drug screening efficiency.
